カテゴリ： GlobalData, 企業調査, 日本

Santen Pharmaceutical Co Ltd (4536)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Santen Pharmaceutical Co Ltd (4536) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10066
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：74
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：日本
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Santen Pharmaceutical Co Ltd (Santen) focuses on the research, development, manufacture and marketing of pharmaceutical products and medical devices. Its product portfolio includes prescription ophthalmic products for bacterial conjunctivitis, glaucoma, dry eye, Inflammation and others; OTC ophthalmic products; anti-allergy ophthalmic products; and medical devices such as intraocular lenses (IOLs) and others. Some of its major brands include Livostin, Alesion, Tarivid, Cosopt, Tapros, Cravit, Diquas Hyalein and others. Santen operates through group companies in Asia, Europe and the US. The company’s R&D activities focus on the development of ophthalmic treatments. Santen is headquartered in Kita-ku, Osaka, Japan.

Santen Pharmaceutical Co Ltd (4536) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Santen Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Santen Pharma Acquires Remaining Portfolio of Ophthalmology Products from Merck 14
Venture Financing 16
RetroSense Therapeutics Raises USD6 Million in Series B Financing Round 16
TearSolutions Raises USD3 Million in Series A Financing Round 17
Clearside Biomedical Raises USD16 Million in Series B Venture Financing 18
Clearside Biomedical Raises US$8 Million In Venture Financing 20
Partnerships 22
Durect Enters into Licensing Agreement with Santen Pharma 22
PeptiDream Enters into Co-Development Agreement with Santen Pharma 23
Aequus Pharma Enters into Agreement with Santen 24
Santen Enters into Research Agreement with twoXAR 25
Santen Pharma Enters into Research Agreement with Riken and Foundation for Biomedical Research and Innovation 26
Santen Pharma to Enter into Agreement with University College London 27
Santen Pharma and Chongqing Kerui Pharma Form Joint Venture 28
Santen Expands Research Agreement with Clearside Biomedical 29
Santen Pharma Enters into Co-Development Agreement with SERI 30
Santen Pharma and Singapore Eye Research Institute Expand Agreement 31
Tracon Pharma Enters Into Co-Development Agreement With Santen Pharma 32
Santen Enters Into Research Agreement With Clearside Biomedical 34
Aqua Therapeutics Enters into Research Agreement with Santen Pharma 35
Regeneron Pharma And Bayer Yakuhin Enter Into Co-Promotion Agreement With Santen Pharma For Eylea 36
Licensing Agreements 38
Santen Pharma Enters into Licensing Agreement with NTC 38
Santen Pharma Enters into Licensing Agreement with Ono Pharma 39
Parion Sciences Enters into Licensing Agreement with Santen Pharma For P-321 40
Santen Extends Licensing Agreement with Eupharmed to Distribute Cationorm 41
Santen Pharma Enters into Licensing Agreement with Oak Pharma 42
Santen Pharma And Eisai Enter Into Option Agreement For Ophthalmic Drugs 43
Asset Transactions 44
Hyperion Pharma Acquires Anti-Rheumatic Pharma Business of Santen Pharma for USD375 Million 44
R-Tech Ueno Acquires Rights to DE-105 from Santen Pharma 45
Akorn Acquires Betimol, Opthalmic Drug, From Santen 46
Santen Pharmaceutical Co Ltd – Key Competitors 47
Santen Pharmaceutical Co Ltd – Key Employees 48
Santen Pharmaceutical Co Ltd – Locations And Subsidiaries 50
Head Office 50
Other Locations & Subsidiaries 50
Recent Developments 53
Financial Announcements 53
Nov 07, 2018: Santen reports consolidated results for Q2 fiscal 2018 53
May 09, 2018: Santen Reports Fiscal 2017 Consolidated Performance 54
Nov 01, 2017: Santen Consolidated Results for Q2 Fiscal 2017 55
Aug 01, 2017: Santen Pharma Reports Revenue Of JPY55.95 Billion In Q1 Fiscal 2018 56
May 10, 2017: Santen Reports Fiscal 2016 Consolidated Performance 57
Feb 07, 2017: Santen Pharma Reports Revenue Of JPY150.7 Billion In Nine Months Ended December 31, 2016 58
Corporate Communications 59
Sep 12, 2018: Santen Pharmaceutical announce personnel changes of representative Director of the Board 59
Jul 17, 2018: Santen Donates to Japan Flood and Landslide Relief Efforts 60
Mar 01, 2018: Luis Iglesias Promoted to Head of Santen EMEA 61
Feb 20, 2018: Santen Announces Appointment of New President 62
Jul 18, 2017: Santen Donates to Northern Kyushu Area Disaster Relief Efforts 63
May 10, 2017: Santen: Notice of Board of Director and Corporate Auditor Nominations 64
Mar 15, 2017: Santen Pharmaceutical: Notice of Corporate Officer Appointments 66
Product News 68
07/26/2017: Santen Receives Positive CHMP Opinion in Europe for Ciclosporin eye drops for the Treatment of Paediatric Patients with Severe Vernal Keratoconjunctivitis 68
07/21/2017: New medicine for rare form of eye allergy in children and teenagers 69
07/10/2018: Santen Pharmaceutical : Receives Marketing Authorisation from the European Commission for DE-076C (Verkazia) as an Orphan Medicinal Product 70
Other Significant Developments 71
Jun 04, 2018: Santen Announces Medium-Term Plan (MTP2020) 71
Feb 20, 2018: Santen Pharmaceutical to Leverage Medidata Edge CTMS to Drive Future Growth in Ophthalmic Clinical Development 72
Apr 07, 2017: Santen Announces Strategic Investment in Regenerative Patch Technologies 73
Appendix 74
Methodology 74
About GlobalData 74
Contact Us 74
Disclaimer 74

List of Tables
Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Santen Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Santen Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Santen Pharma Acquires Remaining Portfolio of Ophthalmology Products from Merck 14
RetroSense Therapeutics Raises USD6 Million in Series B Financing Round 16
TearSolutions Raises USD3 Million in Series A Financing Round 17
Clearside Biomedical Raises USD16 Million in Series B Venture Financing 18
Clearside Biomedical Raises US$8 Million In Venture Financing 20
Durect Enters into Licensing Agreement with Santen Pharma 22
PeptiDream Enters into Co-Development Agreement with Santen Pharma 23
Aequus Pharma Enters into Agreement with Santen 24
Santen Enters into Research Agreement with twoXAR 25
Santen Pharma Enters into Research Agreement with Riken and Foundation for Biomedical Research and Innovation 26
Santen Pharma to Enter into Agreement with University College London 27
Santen Pharma and Chongqing Kerui Pharma Form Joint Venture 28
Santen Expands Research Agreement with Clearside Biomedical 29
Santen Pharma Enters into Co-Development Agreement with SERI 30
Santen Pharma and Singapore Eye Research Institute Expand Agreement 31
Tracon Pharma Enters Into Co-Development Agreement With Santen Pharma 32
Santen Enters Into Research Agreement With Clearside Biomedical 34
Aqua Therapeutics Enters into Research Agreement with Santen Pharma 35
Regeneron Pharma And Bayer Yakuhin Enter Into Co-Promotion Agreement With Santen Pharma For Eylea 36
Santen Pharma Enters into Licensing Agreement with NTC 38
Santen Pharma Enters into Licensing Agreement with Ono Pharma 39
Parion Sciences Enters into Licensing Agreement with Santen Pharma For P-321 40
Santen Extends Licensing Agreement with Eupharmed to Distribute Cationorm 41
Santen Pharma Enters into Licensing Agreement with Oak Pharma 42
Santen Pharma And Eisai Enter Into Option Agreement For Ophthalmic Drugs 43
Hyperion Pharma Acquires Anti-Rheumatic Pharma Business of Santen Pharma for USD375 Million 44
R-Tech Ueno Acquires Rights to DE-105 from Santen Pharma 45
Akorn Acquires Betimol, Opthalmic Drug, From Santen 46
Santen Pharmaceutical Co Ltd, Key Competitors 47
Santen Pharmaceutical Co Ltd, Key Employees 48
Santen Pharmaceutical Co Ltd, Other Locations 50
Santen Pharmaceutical Co Ltd, Subsidiaries 51

List of Figures
Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Santen Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Santen Pharmaceutical Co Ltd (4536)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • AstraZeneca PLC：企業のM&A・事業提携・投資動向
    AstraZeneca PLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's AstraZeneca PLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Jiangsu Hengrui Medicine Co Ltd (600276)：企業の財務・戦略的SWOT分析
    Jiangsu Hengrui Medicine Co Ltd (600276) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Vivus Inc (VVUS)：企業の財務・戦略的SWOT分析
    Vivus Inc (VVUS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Intra-Cellular Therapies Inc (ITCI)：企業の財務・戦略的SWOT分析
    Summary Intra-Cellular Therapies Inc (ITI) is a novel drug manufacturer. The company offers product platform such as ITCI Pipeline that includes lumateperone, ITI-007 platform, PDE inhibitor platform and drug discovery platform. The company’s lead product candidate ITI-007-lumateperone is to treat s …
  • Spark Therapeutics Inc (ONCE)：企業の財務・戦略的SWOT分析
    Summary Spark Therapeutics Inc (Spark) is a clinical-stage gene therapy company which provides gene therapies for inherited retinal diseases (IRDs), neurodegenerative diseases, as well as liver diseases. Its pipeline products include SPK-RPE65, SPK-CHM, rhonova, LHON, SPK-FIX, SPK-FVIII and SPK-TPP1 …
  • Wellcome Trust Sanger Institute-製薬・医療分野：企業M&A・提携分析
    Summary Wellcome Trust Sanger Institute (Sanger Institute), a subsidiary of Genome Research Ltd is a genomic discovery and research centre that carries out research and development in the areas of cellular and human genetics and infection genomics. It also provides postgraduate training on research …
  • AB Sciex LLC：医療機器：M&Aディール及び事業提携情報
    Summary AB Sciex LLC (Sciex), a subsidiary of Danaher Corp, is a provider of life science analytical technologies. The company provides mass spectrometry solutions combined with capillary electrophoresis and liquid chromatography. Its product portfolio includes liquid chromatography-mass spectromete …
  • Berjaya Corporation Berhad：企業の戦略・SWOT・財務分析
    Berjaya Corporation Berhad - Strategy, SWOT and Corporate Finance Report Summary Berjaya Corporation Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • PT. Bank Rakyat Indonesia (Persero) Tbk.：企業の戦略・SWOT・財務情報
    PT. Bank Rakyat Indonesia (Persero) Tbk. - Strategy, SWOT and Corporate Finance Report Summary PT. Bank Rakyat Indonesia (Persero) Tbk. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Stagecoach Group plc：企業の戦略・SWOT・財務分析
    Stagecoach Group plc - Strategy, SWOT and Corporate Finance Report Summary Stagecoach Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Imobiliaria Construtora Grao-Para SA：企業の戦略・SWOT・財務情報
    Imobiliaria Construtora Grao-Para SA - Strategy, SWOT and Corporate Finance Report Summary Imobiliaria Construtora Grao-Para SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Evonik Industries AG (EVK)：製薬・医療：M&Aディール及び事業提携情報
    Summary Evonik Industries AG (Evonik), a subsidiary of RAG-Stiftung, is a specialty chemicals company. Its product portfolio includes surfactants, polymers, resins, additives and others. The company’s products find application in various markets, including adhesives and sealants, automotive, agricul …
  • Vericel Corp (VCEL)-医療機器分野：企業M&A・提携分析
    Summary Vericel Corp (Vericel) formerly Aastrom Biosciences, Inc. is a medical device company that develops patient-specific expanded cellular therapies to repair and regenerate damaged tissue for the treatment of severe, chronic ischemic cardiovascular diseases. It markets two autologous cell thera …
  • TheraVida Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary TheraVida Inc (TheraVida) is a clinical stage specialty pharmaceutical company focused on the development of new therapies for the treatment of primary focal hyperhidrosis. The company’s lead candidate THVD-102 is an oral acting drug used for the treatment of primary and secondary focal hype …
  • Rite Aid Corporation：企業の戦略・SWOT・財務分析
    Rite Aid Corporation - Strategy, SWOT and Corporate Finance Report Summary Rite Aid Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Da Afghanistan Breshna Sherkat：企業の戦略的SWOT分析
    Da Afghanistan Breshna Sherkat - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • OraSure Technologies Inc (OSUR)：企業の財務・戦略的SWOT分析
    OraSure Technologies Inc (OSUR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Restalia Grupo de Eurorestauracion SL：企業の戦略・SWOT・財務分析
    Restalia Grupo de Eurorestauracion SL - Strategy, SWOT and Corporate Finance Report Summary Restalia Grupo de Eurorestauracion SL - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Trimble Inc (TRMB)：企業の財務・戦略的SWOT分析
    Trimble Inc (TRMB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Compass Diversified Holdings LLC：企業のM&A・事業提携・投資動向
    Compass Diversified Holdings LLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Compass Diversified Holdings LLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on merge …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆